Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
13,446
datasets available to search
ShareScore release 0.9.0
Dataset results
13,446 results for “targeted”
COMPREHENSIVE LIVESTOCK HEALTH PROGRAM: TARGETED TREATMENT AND HOLISTIC INTERVENTIONS FOR MAJOR PREVALENT DISEASES IN THE LIVESTOCK FARMING COMMUNITY OF DAYNILE DISTRICT, MOGADISHU, SOMALIA.
<p>The general objective of this project was to intervene with the most common livestock diseases in Dayniile district by carrying out a comprehensive campaign for treatment and control. The specific objectives consisted of a treatment campaign, improving infrastructure for establishing disinfectant foot dips and hand washing points, providing disinfectant tools, and finalising community engagement and education by doing training at the farm level.<br>The team visited different donors and added their contribution. After collecting sufficient funds from various sources, the team began the procurement of the necessary materials. This included purchasing veterinary drugs and supplies from local pharmacies and other essentials like stationery. The first activity was treatment campaigns, which were a central aspect of the project. Over 290 animals were treated for various diseases and conditions. The farm manager was informed of the diagnoses, and upon receiving their permission, the appropriate treatments were administered. The second intervention action was a vaccination campaign. The team vaccinated a total of 70 animals against clostridial bacteria, which is one of the most common camel diseases encountered in the area. The third intervention was the establishment of biosecurity facilities at select livestock farms. Among all the farms involved in the project, five were chosen for the provision of enhanced biosecurity measures. These measures included the installation of foot dips and teat dips. The fourth activity was educating livestock farmers on strategies for controlling and preventing livestock diseases. The training was held at Beder Camel Dairy Farm and attended by approximately 10 individuals, comprising 3 females and 7 males. The content of the training was three modules: the first was general farm biosecurity, the second was operational biosecurity, and the third was concern for vaccination. Recommendation: We recommend that each farm hire livestock health specialists to easily implement disease prevention steps and promptly solve each new case.<br> We recommend the livestock association, veterinary clinics, and other institutions working on livestock do routine campaigns that facilitate the determination of prevalent diseases and the treatment of those cases</p>
Dataset underlying the publication: "Organic contaminants in bio-based fertilizer treated soil: Target and suspect screening approaches" DOI: 10.1016/j.chemosphere.2023.139261
<p>Dataset underlying the publication "Organic contaminants in bio-based fertilizer treated soil: Target and suspect screening approaches" DOI: 10.1016/j.chemosphere.2023.139261.</p>
Interstage single ventricle heart disease infants show dysregulation in multiple metabolic pathways: targeted metabolomics analysis - Data
<p>The data in this Zenodo entry corresponds to the data used to produce the results in <a href="https://www.jacc.org/doi/full/10.1016/j.jacadv.2022.100169">https://www.jacc.org/doi/full/10.1016/j.jacadv.2022.100169</a>. The zipped folder contains three files</p> <ul> <li>Metabolite Data.csv - The meatobilte measurements for all the samples</li> <li>Clinical Data.csv - Values for the clinical variables</li> <li>Clinical Data Descriptions.csv - More in depth explanation of clinical variables as well as possible values of the variables</li> </ul> <p><span>This study was supported by the American Heart Association (AHA</span><span>20CDA35310498 and AHA18IPA34170070) and the National Institutes </span><span>of Health (NIH/NCATS Colorado CTSA, No. UL1 TR001082 and NIH/</span><span>NHLBI K23HL12363</span></p>
Datasets for "Advancing Drug-Target Interactions Prediction: Leveraging a Large-Scale Dataset with a Rapid and Robust Chemogenomic Algorithm"
<p>All datasets required to reproduce the results of publication "Drug-Target Interactions Prediction at Scale: the Komet Algorithm with the LCIdb Dataset"</p>
Predictive models for off-target binding profiles generation
<p>Models for predicting off-target binding, built with Conformal Prediction, and the <a href="http://cpsign-docs.genettasoft.com">CPSign software</a>. The dataset is part of an upcoming publication (Manuscript in preparation), which will provide more details.</p> <p>The dataset is a GZipped Tar archive, with the models as Java Archive (JAR) files. For every JAR-file, there is also a corresponding audit log, with the extension ".audit.json", produced by the workflow software (<a href="http://scipipe.org">SciPipe</a>) used to train the models. This audit file contains all the shell commands used in the workflow that produced the models.</p>
Human Family With Sequence Similarity 83 Member B (FAM83B); A Target Enabling Package
<p>FAM83A-H are newly identified oncogenes characterised by a conserved DUF1669 domain. FAM83B can substitute for RAS to promote malignant transformation. Ablation of FAM83B or mutation of Lys230 inhibits malignant phenotypes, implicating FAM83B as potential therapeutic target. As part of this TEP, we solved the first crystal structures from the FAM83 family, including FAM83A and FAM83B. The structures of the DUF1669 domain reveal a phospholipase D-like fold lacking conservation of key catalytic residues. We deorphanise the FAM83 DUF1669 domain as a critical docking scaffold for binding of casein kinase 1 isoforms. Finally, using XChem fragment screening we report chemical fragments that bind to Lys230 in the central pocket of the DUF1669 and form starting points for potential drug development.</p>
Human Poly (ADP-ribose) Polymerase Family Member 14 (PARP14); A Target Enabling Package
<p>This work provides reagents to develop specific inhibitors of the macrodomains of PARP14, for potential use for cancer and/or inflammation. Targeting the macrodomains of PARP14 is an alternative targeting strategy to PARP catalytic domain inhibitors that may allow greater inhibitor selectivity, and an alternative cellular effect.</p> <p>This package includes protein purification protocols, crystal structures of the 2nd and 3rd macrodomain of PARP14 in complex with small molecule chemical starting points, <em>in vitro </em>assays to measure ligand binding to the macrodomains, as well as validation of a PARP14 antibody and reagents to generate PARP14 knock-out cell lines (CRISPR-Cas9).</p>
Human RECQL5 helicase; A Target Enabling Package
<p>RECQL5 is a member of the RecQ family of helicase which have important functions in DNA repair pathways and maintenance of genome integrity. RECQL5 has recently been identified as a synthetic lethal candidate in various haematological malignancies and has been verified by knockdown to sensitize myeloproliferative neoplasms (MPN) to DNA damaging agents. In this TEP we have expressed purified and determined the first ever crystal structures of RECQL5, in both APO and ADP/Mg2+ bound forms which crystallize in two distinctly different conformations. In vitro DNA stimulated ATPase assays suitable for high throughput screening have been developed as well as lower throughput orthogonal assays to verify potential hits. A fragment screening campaign has been initiated and single fragment hit has identified a potential allosteric site that may be targeted to block the transition between conformations that it thought to be part of the helicase mechanism. Finally included as part of the package we present 3 validated RECQL5 binding nanobodies, one of which is a potent inhibitor of RECQL5 ATPase activity and is suitable for use as a tool reagent to investigate inhibition of RECQL5 and its complexes in vitro.</p>
Human Lysine Demethylase JMJD1B (KDM3B); A Target Enabling Package
<p>There are 3 members of the Lysine Demethylase JMJD1 (KDM3) family, JMJD1A-C. SGC Oxford has expressed, purified and crystallized the catalytic domains of JMJD1A, JMJD1B and JMJD1C as part of the probe programme. Fragment screening and X-ray crystallography identified a large number of binders, some of which were progressed into a medicinal chemistry programme. Despite significant effort molecules with probe properties were not obtained. Consequently it has been decided to put the information generated into the public domain.</p>
Human Lysine Demethylase JMJD2D (KDM4D); A Target Enabling Package
<p>There are 4 members of the Lysine Demethylase JMJD2 (KDM4) family. SGC Oxford has expressed, purified and crystallized the catalytic domains of JMJD2A, JMJD2B, JMJD2C and JMJD2D as part of the probe programme. Fragment screening and X-ray crystallography identified a large number of binders, some of which were progressed into a medicinal chemistry programme. Despite significant effort molecules with probe properties were not obtained. Consequently it has been decided to put the information generated into the public domain.</p>
Supplementary data to accompany "phyloFlash: A pipeline for rapid SSU rRNA-targeted profiling of metagenomes"
<p>Usage examples of the phyloFlash pipeline applied to shotgun metagenomic data sets.</p> <p>The phyloFlash software is available from https://github.com/HRGV/phyloFlash. Examples were generated with phyloFlash v3.3b.</p>
S51 | WRIGCHRMS | GC-HRMS target list of WRI
<p>This is the collection associated with list S51 WRIGCHRMS on the NORMAN Suspect List Exchange.</p> <p><a href="https://www.norman-network.com/?q=suspect-list-exchange">https://www.norman-network.com/?q=suspect-list-exchange</a></p> <p>S51</p> <p>WRIGCHRMS</p> <p><strong>GC-HRMS target list of WRI</strong></p> <p>WRIGCHRMS <a href="https://www.norman-network.com/sites/default/files/files/suspectListExchange/080419Update/WRIGCHRMS_04042019.xlsx">XLSX</a>, <a href="https://www.norman-network.com/sites/default/files/files/suspectListExchange/080419Update/WRIGCHRMS_04042019.csv">CSV</a> (04/04/2019)</p> <p>WRIGCHRMS <a href="https://www.norman-network.com/sites/default/files/files/suspectListExchange/080419Update/WRIGCHRMS_InChIKeys_04042019.txt">InChIKeys</a> (04/04/2019)</p> <p>GC-HRMS target list of WRI. The method was established by Agilent. The list was provided by Michal Kirchner (Slovak Water Research Institute, WRI) and curated by Nikiforos Alygizakis (EI/UoA)</p>
Phenome-wide association studies across large population cohorts support drug target validation
<p>Summary-level data generated by Genomics plc as presented in:<br> Diogo, D. et al. Phenome-wide association studies across large population cohorts support drug target validation. Nat. Commun. 9, 4285 (2018). https://doi.org/10.1038/s41467-018-06540-3</p> <p>If you have any questions or comments regarding these files, please contact Genomics plc at <a href="mailto:research@genomicsplc.com">research@genomicsplc.com</a></p> <p>NOTES<br> -----------------------------<br> These analyses were carried out using the interim UK Biobank imputation data release. Analyses were restricted to a subset of "white-British" unrelated samples with a maximum sample size of 112,337 individuals. </p> <p>Case control phenotypes were defined based on categorical datafields as listed in the accompanying file. <br> Quantitative phenotypes were either rank-normalised before analysis, or beta/se values were standardised after analysis using the variance of the phenotype. The normalisation value is indicated in the accompanying file.<br> <br> All analyses included Age at assessment, sex, genotyping chip, and 10 principal components as covariates. </p> <p>We used plink1.9 linear/logistic regression as appropriate. For chromosome X variants males were treated as having 0 or 2 alternative alleles. </p> <p>The results are not adjusted for genomic control.</p> <p>DATA FILE CONTENT DESCRIPTION<br> -----------------------------<br> CHR - Chromosome<br> SNP - Variant rsID<br> ALT - Alternative allele (effect allele)<br> REF - Reference Allele (non-effect allele)<br> BP - Position in base pairs (b37, 1-based)<br> NMISS - Number of samples with non-missing genotypes<br> BETA - Effect size (log odds ratio or standardised effect size)<br> SE - Standard error<br> P - P-value<br> F_MISS - genotype missing rate<br> P_hwe - Hardy-weinberg p-value<br> MAF - ALT allele frequency</p>
Human Kelch-like ECH Associated Protein 1 (KEAP1); A Target Enabling Package
<p>KEAP1 is a highly redox-sensitive member of the BTB-Kelch family that assembles with the CUL3 protein to form a Cullin-RING E3 ligase complex for the degradation of NRF2. Oxidative stress disables KEAP1 allowing NRF2 protein levels to accumulate for the transactivation of critical stress response genes. Consequently, the KEAP1-NRF2 system is a highly attractive target for the development of protein-protein interaction inhibitors that will stabilise NRF2 for therapeutic effect in conditions of neurodegeneration and inflammation. As part of this TEP we have solved the first crystal structure of a KEAP1-CUL3 complex as well as a structure of the apo-Kelch domain suitable for small molecule soaking. We further established a selectivity assay panel of 17 human Kelch domain-containing proteins and have shown that non-covalent KEAP1 inhibitors from the literature are highly selective for KEAP1. This protein panel offers a resource for future work on KEAP1 as well as 16 other human Kelch proteins.</p>
List of (tentatively) identified non-target structures
<p>This is a list of candidate structures of organic contaminants (tentatively) identified in a riverbank filtration system in The Netherlands by non-target screening of high-resolution mass spectrometry data (associated with ACS Publication <a href="https://doi.org/10.1021/acs.est.9b01750">10.1021/acs.est.9b01750</a>).</p>
Closed-loop auditory stimulation targeting alpha and theta oscillations during REM sleep induces phase-dependent power and frequency changes
<p>This repository contains raw data, sleep scoring, and data to create the figures for the paper:</p> <p><strong>"Closed-loop auditory stimulation targeting alpha and theta oscillations during REM sleep induces phase-dependent power and frequency changes"</strong></p> <p>by Valeria Jaramillo, Henry Hebron, Sara Wong, Giuseppe Atzori, Ullrich Bartsch, Derk-Jan Dijk*, Ines R. Violante* (* contributed equally).</p> <p>Journal article has been published in SLEEP and can be found here: <a href="https://doi.org/10.1093/sleep/zsae193">https://doi.org/10.1093/sleep/zsae193</a></p> <p>Code can be found here: <a href="https://gitlab.surrey.ac.uk/nemo/RSN">https://gitlab.surrey.ac.uk/nemo/RSN</a></p> <p>Please cite as indicated under 'Citation' on this page.</p> <p>More information on the datafiles can be found in the README.</p>
Location of ground stations, targets and spacecraft for Spire Global case study
<p>Datasets for case study in article:<br> "Data sink selection using consensus leadership: improving target connectivity for a spacecraft constellation"</p>
Urea Transporter B (UT-B; SLC14A1); A Target Enabling Package
<p>UT-B is a member of urea transporter family, which consists of two members (UT-A and UT-B). UT-B is primarily a urea channel transporting urea molecules across plasma membrane by concentration gradient. While UT-B is widely expressed, it is particularly important in red blood cells (RBCs). UT-B is associated with improved response to hydroxyurea treatment in sickle cell diseases due to its transport of hydroxyurea into RBCs, and it is the primary antigen for Kidd (Jk) blood group as well as an accessory protein for ABO blood group. UT-B is responsible for urea transport in the vasa recta of kidney, with secondary effect on controlling the urine volume. This makes UT-B a potential target for the development of a new class of diuretics. This TEP presents the structure of UT-B in apo and inhibitor-bound states, determined by crystallography and cryo-electron microscopy, respectively. We have also confirmed the binding of an inhibitor molecule to UT-B <em>in vitro</em> using a biophysical assay. These enable the molecular characterisation of UT-B as an important blood antigen and will also aid further improvement of the inhibitors as a novel therapy for diuretics and potentially neurodegenerative disorders.</p>
Major facilitator superfamily domain-containing protein 10 (MFSD10) A Target Enabling Package (TEP)
<p>MFSD10 (also known as TETRAN in humans) has been proposed to function as an organic anion efflux pump and as a transporter for some NSAIDs. We have produced milligram quantities of purified recombinant protein and solved its structure in an outward-facing state at 2.6 Å resolution by X-ray crystallography. The structure - the first example for a human atypical SLC - provides the initial clues to understanding the broad specificity of its putative substrate-binding site.</p>
Cyclin-Dependent Kinase-Like 5 (CDKL5); A Target Enabling Package
<p>The protein kinase CDKL5 is best known for harbouring loss of function mutations that cause a variant of Rett syndrome, CDKL5 deficiency disorder, that predisposes to seizures and mental retardation. Recent kinome-wide screening has identified CDKL5 as a therapeutic target to ameliorate acute kidney injury, which is a common complication of hospitalisation that can lead to chronic kidney disease. There are currently no proven treatments. We prepared recombinant proteins for the kinase domains of CDKL1, CDKL2, CDKL3 and CDKL5 and solved the structures of these kinases in complex with identified inhibitors at resolutions from 1.5 to 2.4 Å. Overall, the structures capture the kinases with both active and inactive conformations and provide a model to explain the effects of CDKL5 mutation. An <em>in vitro</em> kinase assay showed the importance of a C-terminal αJ helix for the activity of CDKL2 and CDKL3, but not CDKL1 and CDKL5. Functional analyses of the single orthologue in C. elegans CDKL-1 also suggested that CDKL proteins can limit cilia length, which could potentially contribute to the neurological defects in CDKL5 deficiency syndrome. AST-487 and ASC67 present inhibitors of CDKL5 that could be developed for treating acute kidney injury. However, future work is needed to improve selectivity in this drug development.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.